This site is intended for healthcare professionals
Clinical trials
  • Home
  • /
  • Clinical trials
  • /
  • Imbruvica
  • /
  • A Randomized, Double-Blind, Placebo-Controlled Pha...
Clinical trial

A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Either Bendamustine and Rituximab (BR) or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednis

Read time: 2 mins
Last updated:31st Jan 2014
Identifier: NCT01974440
The purpose of this study is to evaluate the efficacy and safety of PCI-32765 (ibrutinib) administered in combination with either bendamustine and rituximab (BR) or rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in adult participants with previously treated indolent Non-Hodgkin lymphoma.
Category Value
Date last updated at source 2017-06-01
Study type(s) Interventional
Expected enrolment 403
Study start date 2014-01-31
Estimated primary completion date 2017-10-09

View full details